Cappello Joseph
Chief Technical Officer at GNLX
- Sold, on record
- $154k
- Dollars the filings state
- Form 4 sales
- 8
- Latest Aug 31, 2026
- Form 144 notices
- 1
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- GNLXGENELUX CorpChief Technical Officer
Sales by reason
Form 4 sales per year, every sale on record.
Timeline
- 1 Form 4 sale GNLXUnusualAug 18, 2023 2023
Sold 3,265 shares at $23.73 ($77k)
Cappello Joseph, VP, Pharmaceutical Development
No 10b5-1 planSold 36.3% of holdings ($214k position)5,735 shares leftFirst sale on recordFollows a Form 144Filing
- 2 Form 4 sale GNLXUnusualDec 16, 2024 +486 days
Sold 6,300 shares at $2.34 ($15k)
Cappello Joseph, VP, Pharmaceutical Development
No 10b5-1 planSold 30.1% of holdings ($49k position)14,653 shares leftFiling
- 3 Form 4 sale GNLXNo planMay 12, 2025 +147 days
Sold 4,737 shares at $2.92 ($14k)
Cappello Joseph, VP, Pharmaceutical Development
No 10b5-1 planSold 8.3% of holdings ($166k position)52,266 shares leftFiling
- 4 Form 4 sale GNLXNo planNov 17, 2025 +189 days
Sold 3,706 shares at $3.88 ($14k)
Cappello Joseph, Chief Technical Officer
No 10b5-1 planSold 2.3% of holdings ($619k position)156,060 shares leftFiling
- 5 Form 4 sale GNLXNo planMar 24, 2026 +127 days
Sold 906 shares at $2.42 ($2k)
Cappello Joseph, Chief Technical Officer
No 10b5-1 planSold 0.6% of holdings ($378k position)155,154 shares left0.2x usual sizeFiling
- 6 Form 4 sale GNLXNo planMay 11, 2026 +48 days
Sold 605 shares at $2.97 ($2k)
Cappello Joseph, Chief Technical Officer
No 10b5-1 planSold 0.4% of holdings ($461k position)154,549 shares left0.1x usual sizeFiling
- 7 Form 4 sale GNLXNo planAug 4, 2026 +85 days
Sold 653 shares at $2.95 ($2k)
Cappello Joseph, Chief Technical Officer
No 10b5-1 planSold 0.2% of holdings ($972k position)328,737 shares left0.2x usual sizeFiling
- 8 Form 4 sale GNLXUnusualAug 31, 2026 +27 days
Sold 10,257 shares at $2.74 ($28k)
Cappello Joseph, Chief Technical Officer
No 10b5-1 planSold 3.1% of holdings ($901k position)318,480 shares left4.4x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (9)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | Sep 2, 2026 | GNLX | Chief Technical Officer | Form 4 sale | 10,257 | $28k | 3.1% | Unusual | SEC |
| Aug 4, 2026 | Aug 4, 2026 | GNLX | Chief Technical Officer | Form 4 sale | 653 | $2k | 0.2% | No plan | SEC |
| May 11, 2026 | May 12, 2026 | GNLX | Chief Technical Officer | Form 4 sale | 605 | $2k | 0.4% | No plan | SEC |
| Mar 24, 2026 | Mar 26, 2026 | GNLX | Chief Technical Officer | Form 4 sale | 906 | $2k | 0.6% | No plan | SEC |
| Nov 17, 2025 | Dec 11, 2025 | GNLX | Chief Technical Officer | Form 4 sale | 3,706 | $14k | 2.3% | No plan | SEC |
| May 12, 2025 | May 13, 2025 | GNLX | VP, Pharmaceutical Development | Form 4 sale | 4,737 | $14k | 8.3% | No plan | SEC |
| Dec 16, 2024 | Dec 18, 2024 | GNLX | VP, Pharmaceutical Development | Form 4 sale | 6,300 | $15k | 30.1% | Unusual | SEC |
| Aug 18, 2023 | Aug 22, 2023 | GNLX | VP, Pharmaceutical Development | Form 4 sale | 3,265 | $77k | 36.3% | Unusual | SEC |
| Aug 18, 2023 | Aug 18, 2023 | GNLX | Officer | Form 144 notice | 3,274 | $78k | Notice | SEC |